BR112016006582A2 - terapia combinada laquinimod para o tratamento da esclerose múltipla - Google Patents

terapia combinada laquinimod para o tratamento da esclerose múltipla

Info

Publication number
BR112016006582A2
BR112016006582A2 BR112016006582A BR112016006582A BR112016006582A2 BR 112016006582 A2 BR112016006582 A2 BR 112016006582A2 BR 112016006582 A BR112016006582 A BR 112016006582A BR 112016006582 A BR112016006582 A BR 112016006582A BR 112016006582 A2 BR112016006582 A2 BR 112016006582A2
Authority
BR
Brazil
Prior art keywords
treatment
laquinimod
multiple sclerosis
combination therapy
present
Prior art date
Application number
BR112016006582A
Other languages
English (en)
Portuguese (pt)
Inventor
Kaye Joel
Knappertz Volker
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of BR112016006582A2 publication Critical patent/BR112016006582A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
BR112016006582A 2013-09-27 2014-09-26 terapia combinada laquinimod para o tratamento da esclerose múltipla BR112016006582A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361883698P 2013-09-27 2013-09-27
PCT/US2014/057705 WO2015065628A2 (en) 2013-09-27 2014-09-26 Laquinimod combination therapy for treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
BR112016006582A2 true BR112016006582A2 (pt) 2017-08-01

Family

ID=52740749

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016006582A BR112016006582A2 (pt) 2013-09-27 2014-09-26 terapia combinada laquinimod para o tratamento da esclerose múltipla

Country Status (16)

Country Link
US (3) US20150094332A1 (cg-RX-API-DMAC7.html)
EP (1) EP3049075A4 (cg-RX-API-DMAC7.html)
JP (1) JP2016533323A (cg-RX-API-DMAC7.html)
KR (1) KR20160085757A (cg-RX-API-DMAC7.html)
CN (1) CN105848653A (cg-RX-API-DMAC7.html)
AR (1) AR097792A1 (cg-RX-API-DMAC7.html)
AU (1) AU2014342917A1 (cg-RX-API-DMAC7.html)
BR (1) BR112016006582A2 (cg-RX-API-DMAC7.html)
CA (1) CA2925493A1 (cg-RX-API-DMAC7.html)
EA (1) EA201690673A1 (cg-RX-API-DMAC7.html)
IL (1) IL244620A0 (cg-RX-API-DMAC7.html)
MX (1) MX2016003763A (cg-RX-API-DMAC7.html)
SG (1) SG11201602175VA (cg-RX-API-DMAC7.html)
TW (1) TW201601722A (cg-RX-API-DMAC7.html)
UY (1) UY35748A (cg-RX-API-DMAC7.html)
WO (1) WO2015065628A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1231413A1 (zh) 2014-04-29 2017-12-22 Teva Pharmaceutical Industries Ltd. 用於治疗具有高残疾状况的复发-缓解型多发性硬化症(rrms)的患者的拉喹莫德

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
US20080227847A1 (en) * 2005-07-07 2008-09-18 Aditech Pharma Ab Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use
CN101466379B (zh) * 2006-06-12 2012-10-31 泰华制药工业有限公司 稳定的拉喹莫德的制剂
NZ597378A (en) * 2009-06-19 2014-08-29 Teva Pharma Treatment of multiple sclerosis with laquinimod
SG10201606191PA (en) * 2011-07-28 2016-09-29 Teva Pharma Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate

Also Published As

Publication number Publication date
CA2925493A1 (en) 2015-05-07
IL244620A0 (en) 2016-04-21
SG11201602175VA (en) 2016-04-28
JP2016533323A (ja) 2016-10-27
WO2015065628A3 (en) 2015-10-29
CN105848653A (zh) 2016-08-10
AR097792A1 (es) 2016-04-13
US20160271094A1 (en) 2016-09-22
TW201601722A (zh) 2016-01-16
UY35748A (es) 2015-04-30
WO2015065628A2 (en) 2015-05-07
AU2014342917A1 (en) 2016-04-21
KR20160085757A (ko) 2016-07-18
EP3049075A4 (en) 2017-05-03
EA201690673A1 (ru) 2016-08-31
MX2016003763A (es) 2016-10-28
US20170304253A1 (en) 2017-10-26
US20150094332A1 (en) 2015-04-02
EP3049075A2 (en) 2016-08-03

Similar Documents

Publication Publication Date Title
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
BR112015022538A2 (pt) terapia de indução de rituximab seguida por terapia de acetato de glatirâmero
EA201491773A1 (ru) Лечение рассеянного склероза комбинацией лаквинимода и диметилфумарата
BR112014008731A2 (pt) tratamento de esclerose múltipla com combinação de laquinimode e fingolimode
BR112015016997A2 (pt) composto, composição farmacêutica e método para o tratamento ou prevenção de câncer de mama
BR112014032699A2 (pt) métodos de tratamento de síndrome metabólica pediátrica
BR112016003201A2 (pt) inibidores de grp94 seletivos e usos dos mesmos
MX2014001050A (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero.
PH12014502757B1 (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
BR112014019399A2 (pt) métodos de tratamento da fibrose
NZ702087A (en) Pharmaceutical compositions and treatment of mastitis
BR112015026238A2 (pt) tratamento de câncer com dihidropirazino-pirazinas
BR112012033738A2 (pt) método para o tratamento de transtorno bipolar
BR112015019564A2 (pt) tratamento de esclerose múltipla com laquinimod
EA201591180A1 (ru) Составы ингибитора lfa-1
BR112015000616A2 (pt) tratamento da esclerose múltipla com combinação de laquinimode e fampridina
BR112015006063A2 (pt) compostos heteroaromáticos, processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica
BR112015028516A2 (pt) tratamento ou prevenção de distúrbios neurodegenerativos com o uso de mentol, linalol e/ou icilina
BR112014016450A2 (pt) composto antagonista de leucotrieno b4
BR112015028884A2 (pt) tratamento ou prevenção de depressão utilizando mentol e/ou icilina
BR112017002449A2 (pt) tratamento de sintomas associados com terapia de privação androgênica
MX2016003763A (es) Terapia de combinacion con laquinimod para tratamiento de esclerosis multiple.
MX2016001177A (es) Tratamiento de esclerosis multiple con la combinacion de laquinimod y flupirtina.
BR112015026484A2 (pt) tratamento ou prevenção de dano neuronal não inflamatório de trauma cerebral e acidentes vasculares cerebrais usando mentol, linalool e/ou icilin
BR112015004152A2 (pt) combinação farmacêutica compreendendo um inibidor de fosfatidilinositol 3-quinase e um inibidor da aromatase

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2533 DE 23-07-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.